The second vaccine developed in Russia is EpiVacCorona. There is still little information about this vaccine, which has already been approved by the government, but as of 19 March was not yet being used to immunise the population.
Manufactured by the State Research Center of Virology and Biotechnology VECTOR, EpiVacCorona is a vaccine based on synthetic peptides. Its composition includes a synthetic version of SARS-CoV-2 protein fragments (or peptides) to trigger the immune response in the body. The phase III clinical trial began in November 2020 and involved about 3,000 volunteers from Russia. The results have not yet been published, but officials assured that it offered 100% efficacy during phases I and II. It consists of two doses, administered over 21 to 28 days.
It is not known at this stage whether it causes adverse reactions and there is no information on the temperature at which it should be stored.
We are a team of young journalists from Barcelona who work independently to combat misinformation in our territory and beyond. We rely on facts and data to verify what politicians say and the falsehoods circulating on social media.
We need you. With your contribution, you will contribute to a healthier political debate and help promote educational projects to teach citizens how to navigate information chaos and defend themselves against misinformation.
You can contribute as much as one euro and it won't take you more than 45 seconds (we've counted them). If you can, please mark your contribution as monthly and so we can continue to do our job rigorously and independently. Thank you so much.Donate